Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Radioligand Efficacy Comparison by Initial PSA-Response Outcome in Metastatic CRPC With Lutetium 177Lu PSMA RLT (RECIPROCAL)

NCT07200830 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT07200830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07200830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Radioligand Efficacy Comparison by Initial PSA-Response Outcome in Metastatic CRPC With Lutetium 177Lu PSMA RLT (RECIPROCAL)
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 3
Overall status
Recruiting
Start date
March 31, 2026
Completion date
September 9, 2034
Enrollment
1,524 (estimated)
Sites
138

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate carcinoma, metastatic prostate adenocarcinoma, stage ivb prostate cancer ajcc v8